Over the past two years, AI adoption in life sciences across U.S. healthcare and Life Sciences industry has accelerated rapidly, but not evenly. The share of organizations using AI tools designed for specific tasks, such as clinical documentation and imaging analysis, has grown from about 3% to 22%, with hospitals leading at 27%. Canada shows a similar pattern of growing interest, where an environmental scan identified dozens of active AI initiatives supporting clinical decision-making and care coordination.
Hospitals have moved faster largely because providers face heavy administrative workloads and sustained cost pressure, including rising labor costs. In that context, AI that reduces administrative burden is easier to fund and scale because its impact can be tracked through time saved, lower operating costs, and increased staff capacity.
Why life sciences adoption looks different
A practical way to move beyond pilots is to deliver AI one use case at a time, through focused tools that support a specific decision or workflow. In this context, a “product” is not a drug or platform, but a usable data solution, such as a dashboard or AI-enabled support tool, embedded in real work. Teams start with one tool tied to a clear outcome, put it into use, measure results, and then expand incrementally based on what proves valuable, rather than attempting broad deployment upfront.
This approach works for two reasons. First, when a tool is embedded in day-to-day activities, gaps in data quality, access, and process design surface quickly because they affect daily work. Fixing those issues becomes part of delivery, rather than a separate data cleanup effort. Second, because each tool is narrowly scoped, it is easier to validate, document, and govern. Leaders can set clear guardrails through data governance and AI governance and confirm the tool performs reliably in one workflow before expanding its use elsewhere.
Two practical starting points for life sciences companies illustrate this approach:
- R&D Portfolio Executive Dashboard: A regularly refreshed view that consolidates pipeline status, milestones, spend versus budget, and emerging risks across R&D and clinical programs. Outcome: less time assembling reports, faster decisions on where to focus attention and resources.
- Quality and Compliance AI Assistant: An LLM-based tool trained on internal SOPs, deviations, and regulatory guidance that helps teams find answers and summarize documentation. Outcome: less time searching manuals and audit materials, more consistent compliance workflows.
Each example is narrow by design, helping teams build confidence in data, controls, and outcomes before expanding further. As more products are delivered, AI adoption in life sciences scales through proven results and reusable patterns, often expanding from R&D into manufacturing, regulatory, supply chain, and commercial functions, with progress compounding over time.
Where to start
For life sciences leaders looking to advance AI in a practical way, a strong starting point is one high-impact use case delivered as a focused data product with clear success metrics. This progression, from an initial use case to repeatable, governed delivery, reflects Kirke’s signature framework, the Data Confidence Path™. Kirke can support this journey, from selecting and prioritizing the right use case, to assessing data and governance readiness and delivering solutions embedded in regulated workflows.
A first successful product provides tangible proof of value, such as faster decisions, reduced manual effort, or clearer operational visibility, while establishing repeatable ways of working. Over time, this enables organizations to scale AI more reliably, improve execution across R&D and operations, and turn data and AI into a sustained source of business advantage rather than a series of isolated experiments.
Sources
- Menlo Ventures – 2025: The State of AI in Healthcare
https://menlovc.com/perspective/2025-the-state-of-ai-in-healthcare/
- Digital Health Canada – AI in Action (Chief Executive Forum initiatives)
https://digitalhealthcanada.com/membership/chief-executive-forum/inititatives/ai-in-action/
- American Hospital Association
https://www.aha.org/press-releases/2024-05-02-new-aha-report-hospitals-and-health-systems-continue-face-rising-costs-economic-pressures?utm_source=chatgpt.com
- Deloitte – 2026 Life Sciences Executive Outlook
https://www.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2026-life-sciences-executive-outlook.html
- FDA – PCCP / AI-ML enabled device software functions
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/artificial-intelligence-enabled-device-software-functions-lifecycle-management-and-marketing
- National Academy of Medicine, Taking Action Against Clinician Burnout: A Systems Approach to Professional Well-Being. Highlights for Policymakers (sector brief, based on the 2019 NASEM report)
https://nam.edu/taking-action-against-clinician-burnout-a-systems-approach-to-professional-well-being
